Skip to content

NasaPharm

Active
Private limited companyfounded 20251 yr activeRue Thier du Ry 5, 4671 Blégny, BelgiumKBO/BCE: BE 1019.084.374
Summary

NasaPharm has been active since 2025 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show negative equity (-€21,265) and a net result of -€46,265. Its solvency ranks better than 13% of 524 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.9% (low).

Checked score

Score 2025
44 / 100
Weak
Negative equity caps the score. Every signal that weighs is under Signals.
Axes
Profitability18
Solvency21
Growth-
Track record67
Bankruptcy probability, 12 months
0.9% Low
0%0.5%1.5%4%10%≥ 25%
No credit on open account
short-term debt: 0.9% and cash: 98.6% of total assets, and equity is negative.
Credit check for your own amount and term

Open the credit simulator : see how the verdict changes with amount, term and advance.

Signals

Six signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
raises risk · Young company
A young company has little track record yet and statistically fails more often than an established one.
KBO · incorporation date
Age against the risk zone
highest failure risk from 2 to 8 years 1 year 0 10 y
lowers risk · Lower-failure-rate sector
In this sector companies fail less often than the Belgian average.
Gazette · bankruptcies per sector, NACE 72
Relative position
BE, all sectors
reference
Scientific research and development (NACE 72)
about 30% fewer bankruptcies
← fewer bankruptcies more bankruptcies →
raises risk · Annual accounts: weaker financial profile
The latest annual accounts show a weaker profile in solvency, result or liquidity than companies that stay afloat.
NBB · annual accounts 2025
Solvency, return and age of the figures
Solvency
-3.5%
Return on assets
-7.6%
Age of the figures
9 mo
raises risk · Higher-failure-rate region
In this region companies fail more often than in the rest of the country.
KBO · registered office
raises risk · Negative equity
The 2025 annual accounts show negative equity and a net loss.
NBB · annual accounts 2025
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 09-07-2026, 22 days ahead of the deadline.
NBB · 1 filing
Deviation from the deadline
2025
22 d early
← before the deadline after the deadline →
Checked, nothing found (1)
neutral · No strike-offs in the KBO publications
We found no ex-officio strike-off or cessation. Our series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.
KBO publications · our coverage

History

NasaPharm was incorporated on 23 January 2025 as a Private limited company.1 The company has filed annual accounts once, for fiscal year 2025.2

  1. 1Crossroads Bank for Enterprises
  2. 2National Bank, annual accounts 2025

Go further with this company

Is this your company? See how customers and banks see it.

Investigating this company? Keep it with today's facts in a case file.

Financials · fiscal year 2025, micro schema

Equity
-€21,265
Total assets
€606,267
Net result
-€46,265
Working capital
€600,561

Turnover and EBIT margin not published: the micro schema does not require them.

Key figures and ratios
2025 value
Solvency
-3.5%
Debt to equity
-29.51
ROA
-7.6%
Debt
€627,532
Debt ≤ 1 year
€5,706
Debt > 1 year
€621,826
A ratio outside any meaningful range has been withheld (balance sheet total €606,267, equity -€21,265).

Peer companies

Historical observation

Of the 152 companies that looked in July 2024 the way this one looks now, 0% went bankrupt within 24 months and 99% are still going.

  • Small
  • under 2 years old
  • negative equity
  • a small loss
0% went bankrupt
0.7% stopped otherwise
99% still going

For this company itself Checked computes a higher bankruptcy probability: 0.9% over twelve months. The score reads more about this company than the group's four characteristics; both figures are right about what they measure.

How reliable is this rule?

Tested on the year before, without using that year itself: the groups of July 2023 gave each of the 497,058 companies of July 2024 its group's bankruptcy share. Expected: 1.5%; actually bankrupt within 24 months: 1.6%.

The companies in ten equal groups, from lowest to highest expected share.
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.4%
3 0.5% 0.5%
4 0.6% 0.7%
5 0.8% 0.9%
6 1.2% 1.3%
7 1.5% 1.6%
8 1.7% 1.7%
9 2.7% 2.8%
10 5.3% 5.7%

The rule ranks well: a company that went bankrupt got a higher share than one that kept going in 74% of comparisons. The level follows the economy: in a year with more bankruptcies, the actual share is higher than the year before.

An observation about 152 comparable companies, not a prediction for this company. The sector does not count: the register keeps no sector for companies that stopped, so it would make the outcome look better than it was.

Annual accounts
Filed annual accounts As filed with the NBB · 2025 · 24 lines
Balance sheet Code2025
Assets
Total assets20/58€606,267
Current assets29/58€606,267
Amounts receivable within one year40/41€8,230
Other amounts receivable41€8,230
Cash at bank and in hand54/58€598,037
Equity and liabilities
Total equity and liabilities10/49€606,267
Equity10/15-€21,265
Contributions10/11€25,000
Profit (loss) carried forward14-€46,265
Amounts payable17/49€627,532
Amounts payable after more than one year17€621,826
Financial debts170/4€346,826
Other amounts payable178/9€275,000
Amounts payable within one year42/48€5,706
Trade debts44€5,706
Suppliers440/4€5,706
Income statement Code2025
Gross operating margin9900-€46,221
Operating profit (loss)9901-€46,221
Financial charges65/66B€44
Recurring financial charges65€44
Profit (loss) for the period before taxes9903-€46,265
Profit (loss) for the period9904-€46,265
Profit (loss) for the period to be appropriated9905-€46,265
Appropriation of the result
Profit (loss) to be appropriated9906-€46,265

The notes to these accounts (6 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.

Line2025
Gross operating margin9900-€46,221
Operating profit (loss)9901-€46,221
Financial charges65/66B€44
Recurring financial charges65€44
Profit (loss) for the period before taxes9903-€46,265
Profit (loss) for the period9904-€46,265
Profit (loss) for the period to be appropriated9905-€46,265
Line2025
Assets
Total assets20/58€606,267
Current assets29/58€606,267
Amounts receivable within one year40/41€8,230
Other amounts receivable41€8,230
Cash at bank and in hand54/58€598,037
Equity and liabilities
Total equity and liabilities10/49€606,267
Equity10/15-€21,265
Contributions10/11€25,000
Profit (loss) carried forward14-€46,265
Amounts payable17/49€627,532
Amounts payable after more than one year17€621,826
Financial debts170/4€346,826
Other amounts payable178/9€275,000
Amounts payable within one year42/48€5,706
Trade debts44€5,706
Suppliers440/4€5,706
Line2025
Profit (loss) for the period9904-€46,265
Operating cash flow (approximation)-€46,265

Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.

Download as CSV

Timeline · acts, filings and financial milestones

2026
09-07
NBB filing Annual accounts filed
fiscal year 2025 · micro schema
NBB filing
0 of 1 act read
About the unread acts

We know of 1 Belgian State Gazette act for this company. It has not been read yet: what they contain is neither established nor disproved here.

Have them read with priority Sign in to place this company at the front of the reading queue.

Directors · office · real estate

Directors
1 act for this company is in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Blégny · 1 establishment unit since 2025
seat establishment The establishment unit on the map
Ground area
1,185 m²
Building footprint
155 m²
Volume, LiDAR
657 m³
Parcel 62010A0227/00Y000, Wallonia · tallest building 5.6 m, ±1 floor. Linked by address, not a title deed.
14 companies at this address See who is registered here
1 establishment unit
Rue Thier du Ry 5, 4671 Blégny
Research and development on biotechnology
since 20252.375.709.647
1 parcel
Wallonia 1 (100%)
Parcel (capakey) Region Area Buildings Height / fl.
62010A0227/00Y000 Wallonia 1,185 m² 1 · 155 m² 5.6 m · 1 fl.
Linked by address, not proof of ownership
Good to know
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.

Similar companies · same sector and region

This company's figures show no positive equity and no headcount, so a size comparison is not possible. These companies share only the sector and the region. Of 762 companies in sector 72101 we hold annual accounts for 483. See the whole sector

Identification & contact

Identification
Legal formPrivate limited company
Founded23-01-2025
Fiscal year end31-12
Activities, NACEBEL 2025
72101Research and development on biotechnology
72109Other research and development on natural sciences
E-invoicing
Reachable via Peppol
Peppol ID 0208:1019084374
Also 9925:BE1019084374
Registered 02-02-2026

Register as of 27 September 2026 · Peppol Directory

Scores and ratios are computed by Checked and are not a credit decision.